Medpace (MEDP) to Release Earnings on Monday

Medpace (NASDAQ:MEDP - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Monday, April 21st. Analysts expect Medpace to post earnings of $3.05 per share and revenue of $528.38 million for the quarter. Medpace has set its FY 2025 guidance at 11.930-12.690 EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Price Performance

Shares of MEDP stock traded down $0.22 during mid-day trading on Friday, hitting $296.28. 698,291 shares of the stock traded hands, compared to its average volume of 325,831. The stock's fifty day moving average is $318.52 and its two-hundred day moving average is $333.31. Medpace has a 52-week low of $272.00 and a 52-week high of $459.77. The stock has a market cap of $8.96 billion, a P/E ratio of 23.46, a P/E/G ratio of 3.81 and a beta of 1.46.

Analyst Ratings Changes

MEDP has been the subject of a number of recent analyst reports. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and lowered their target price for the stock from $370.00 to $328.00 in a research note on Monday. Truist Financial dropped their price objective on shares of Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Finally, Mizuho cut their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Medpace has an average rating of "Hold" and a consensus price target of $357.50.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.